Zobrazeno 1 - 10
of 27
pro vyhledávání: '"Mohammad O. Atiq"'
Autor:
Mohammad O. Atiq, Danielle M. Pastor, Fatima Karzai, Amy R. Hankin, Baris Turkbey, Lisa M. Cordes, Isaac Brownell, Yi Liu, Gregory T. Chesnut, Ravi A. Madan
Publikováno v:
Frontiers in Oncology, Vol 13 (2023)
The risks of development of colorectal and endometrial cancers in individuals with Lynch syndrome (LS) are well known and have been widely studied. In recent years, the potential association of other malignancies, including prostate cancer, with LS h
Externí odkaz:
https://doaj.org/article/2cdfa97256cf466fb8839255a06eab2f
Autor:
Philip W. Kantoff, Gouri J. Nanjangud, Gwo-Shu Mary Lee, Lorelei A. Mucci, Wassim Abida, Yu Chen, Nabeela A. Khan, Yuki Yoshikawa, Kalyani Chadalavada, Rahim Hirani, Lina Jehane, Kazumasa Komura, Mohammad O. Atiq, Konrad H. Stopsack, Subhiksha Nandakumar, Ying Z. Mazzu, Joshua Armenia, Goutam Chakraborty
Supplementary Figure S1
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::37dcdfac9a8370cd9b498061f4bdec95
https://doi.org/10.1158/1078-0432.22474049
https://doi.org/10.1158/1078-0432.22474049
Autor:
Philip W. Kantoff, Gouri J. Nanjangud, Gwo-Shu Mary Lee, Lorelei A. Mucci, Wassim Abida, Yu Chen, Nabeela A. Khan, Yuki Yoshikawa, Kalyani Chadalavada, Rahim Hirani, Lina Jehane, Kazumasa Komura, Mohammad O. Atiq, Konrad H. Stopsack, Subhiksha Nandakumar, Ying Z. Mazzu, Joshua Armenia, Goutam Chakraborty
Supplementary Table S5
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2ff07e4fc042fd974a4148024ebbd230
https://doi.org/10.1158/1078-0432.22474007.v1
https://doi.org/10.1158/1078-0432.22474007.v1
Autor:
Philip W. Kantoff, Gouri J. Nanjangud, Gwo-Shu Mary Lee, Lorelei A. Mucci, Wassim Abida, Yu Chen, Nabeela A. Khan, Yuki Yoshikawa, Kalyani Chadalavada, Rahim Hirani, Lina Jehane, Kazumasa Komura, Mohammad O. Atiq, Konrad H. Stopsack, Subhiksha Nandakumar, Ying Z. Mazzu, Joshua Armenia, Goutam Chakraborty
Purpose:Previous sequencing studies revealed that alterations of genes associated with DNA damage response (DDR) are enriched in men with metastatic castration-resistant prostate cancer (mCRPC). BRCA2, a DDR and cancer susceptibility gene, is frequen
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::99f3101586ba558d6603f390b61fb055
https://doi.org/10.1158/1078-0432.c.6528656
https://doi.org/10.1158/1078-0432.c.6528656
Autor:
Philip W. Kantoff, Gouri J. Nanjangud, Gwo-Shu Mary Lee, Lorelei A. Mucci, Wassim Abida, Yu Chen, Nabeela A. Khan, Yuki Yoshikawa, Kalyani Chadalavada, Rahim Hirani, Lina Jehane, Kazumasa Komura, Mohammad O. Atiq, Konrad H. Stopsack, Subhiksha Nandakumar, Ying Z. Mazzu, Joshua Armenia, Goutam Chakraborty
• Figure legends S1 to S6. • Tables S1 and S4, part of Table S8, and Tables S9, S10, and S11.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::440209923e374aa44b42893fcfeb52c2
https://doi.org/10.1158/1078-0432.22474028.v1
https://doi.org/10.1158/1078-0432.22474028.v1
Autor:
Elias Chandran, Meghali Goswami, Renee Nicole Donahue, Mohammad O. Atiq, Fatima Karzai, Marijo Bilusic, Jennifer L. Marte, Philip M. Arlen, Lisa M. Cordes, Helen Owens, Megan Hausler, Amy Hankin, Monique Williams, William L. Dahut, William Douglas Figg, Jeffrey Schlom, James L. Gulley, Ravi Amrit Madan
Publikováno v:
Journal of Clinical Oncology. 41:207-207
207 Background: Docetaxel with androgen deprivation therapy (ADT) has been shown to improve survival in metastatic castration-sensitive prostate cancer (mCSPC). There is limited data on the immunologic effects of docetaxel in mCSPC. Greater knowledge
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::27e7c9a8e53de21e3deadca7f29bcb55
https://doi.org/10.1200/jco.2023.41.6_suppl.207
https://doi.org/10.1200/jco.2023.41.6_suppl.207
Combining IL-12 immunocytokine (M9241) with docetaxel in metastatic prostate cancer: A phase I study
Autor:
Mohammad O. Atiq, Elias Bin Aris Chandran, Luke Meininger, Fatima Karzai, Marijo Bilusic, Jennifer L. Marte, Philip M. Arlen, Lisa M. Cordes, Julius Strauss, Jason Redman, Charalampos S. Floudas, Danielle M. Pastor, Helen Owens, Amy Hankin, Monique Williams, William Douglas Figg, William L. Dahut, Jeffrey Schlom, James L. Gulley, Ravi Amrit Madan
Publikováno v:
Journal of Clinical Oncology. 40:e17033-e17033
e17033 Background: M9241 is an immunocytokine that targets single- and double-stranded DNA which allows the treatment to localize IL-12 to necrotic tumor (Xu, CCR 2017). M9241 was well-tolerated as a monotherapy in a Phase I study with solid tumors (
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::99fc0daa76079f5c82ac78a2bb48d4ca
https://doi.org/10.1200/jco.2022.40.16_suppl.e17033
https://doi.org/10.1200/jco.2022.40.16_suppl.e17033
Autor:
Mohammad O. Atiq, Shruti U. Gandhy, Fatima Karzai, Munjid Al Harthy, Gang Chen, Marijo Bilusic, David James VanderWeele, Elias Bin Aris Chandran, Lisa M. Cordes, Helen Owens, Anna Couvillon, Amy Hankin, Monique Williams, William Douglas Figg, Peter L. Choyke, Liza Lindenberg, Esther Mena, William L. Dahut, James L. Gulley, Ravi Amrit Madan
Publikováno v:
Journal of Clinical Oncology. 40:e17046-e17046
e17046 Background: Multiple treatment options combined with androgen deprivation therapy (ADT) provide a survival advantage in mCSPC. In this prospective study, mCSPC patients were treated with docetaxel and Prostvac, a therapeutic cancer vaccine. Si
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::25d6ee283b5b04f16501721081298bb7
https://doi.org/10.1200/jco.2022.40.16_suppl.e17046
https://doi.org/10.1200/jco.2022.40.16_suppl.e17046
Autor:
Elias Bin Aris Chandran, Mohammad O. Atiq, Renee Nicole Donahue, Fatima Karzai, Marijo Bilusic, Jennifer L. Marte, Philip M. Arlen, Lisa M. Cordes, Helen Owens, Amy Hankin, Monique Williams, William Douglas Figg, William L. Dahut, Jeffrey Schlom, James L. Gulley, Ravi Amrit Madan
Publikováno v:
Journal of Clinical Oncology. 40:130-130
130 Background: Docetaxel is a standard of care for metastatic castration-sensitive prostate cancer (mCSPC). PROSTVAC is a pox viral-based therapeutic cancer vaccine encoding for PSA and three T-cell co-stimulatory molecules. Pox viral-based vaccines
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2d425f6b3a03c9381070f03e9c380d82
https://doi.org/10.1200/jco.2022.40.6_suppl.130
https://doi.org/10.1200/jco.2022.40.6_suppl.130
Autor:
Mohammad O. Atiq, Elias Bin Aris Chandran, Luke Meininger, Fatima Karzai, Marijo Bilusic, Jennifer L. Marte, Philip M. Arlen, Lisa M. Cordes, Julius Strauss, Jason Redman, Charalampos S. Floudas, Danielle M. Pastor, Helen Owens, Amy Hankin, Monique Williams, William Douglas Figg, William L. Dahut, Jeffrey Schlom, James L. Gulley, Ravi Amrit Madan
Publikováno v:
Journal of Clinical Oncology. 40:93-93
93 Background: M9241 is an immunocytokine that targets single- and double-stranded DNA which allows the treatment to localize IL-12 to necrotic tumor (Xu, CCR 2017). M9241 was well-tolerated as a monotherapy in a Phase I study with solid tumors (Stra
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::907d4d68aa8bf9d1c2d240680c92bacf
https://doi.org/10.1200/jco.2022.40.6_suppl.093
https://doi.org/10.1200/jco.2022.40.6_suppl.093